OP-1 LONG-TERM EFFICACY AND SAFETY OF OPEN-LABEL SELADELPAR TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: INTERIM 2-YEAR RESULTS FROM THE ASSURE STUDY Article Swipe
Palak Trivedi
,
Cynthia Levy
,
Kris V. Kowdley
,
Stuart C. Gordon
,
Christopher L. Bowlus
,
Maria Carlota Londoño Hurtado
,
Gideon M. Hirschfield
,
Aliya F. Gulamhusien
,
Eric Lawitz
,
Alejandra Maria Villamil
,
Alma Ladron de Guevara Cetina
,
Marlyn J. Mayo
,
Ziad Younes
,
Oren Shibolet
,
Kidist Yimam
,
Daniel S. Pratt
,
Jeong Heo
,
Ulrike Morgera
,
Pietro Andreoné
,
Andreas E. Kremer
,
Christophe Corpechot
,
Aparna Goel
,
Adam Peyton
,
Hany Elbeshbeshy
,
Daria B. Crittenden
,
Carrie Heusner
,
Sarah Proehl
,
Shuqiong Zhou
,
Charles A. McWherter
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.aohep.2024.101599
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.aohep.2024.101599
Conflict of interest: Yes, Full disclosures sent separately. Introduction and Objectives: Seladelpar reduces biochemical markers of cholestasis and pruritus in patients with primary biliary cholangitis. ASSURE (NCT03301506) is an ongoing, open-label, long-term Phase 3 trial of seladelpar in patients rolling over from Phase 3 RESPONSE (NCT04620733) or legacy studies (NCT03602560, NCT02955602, NCT03301506, and NCT04950764). We report interim 2-year efficacy and safety results. Patients / Materials and Methods: Patients with insufficient response/intolerance to ursodeoxycholic acid could enroll in ASSURE. Key endpoints were composite biochemical response (alkaline phosphatase [ALP] <1.67 × upper limit of normal [ULN], ALP decrease ≥15%, and total bilirubin ≤ULN) and ALP normalization. Pruritus was measured using numerical rating scale (NRS; 0–10). For patients enrolling from RESPONSE, baseline was entry to RESPONSE and analyzed as continuous seladelpar or crossover from placebo; legacy patients were analyzed separately with baseline defined as entry to ASSURE. Results and Discussion: As of 01/2024, 158 RESPONSE and 179 legacy patients received seladelpar 10 mg daily for up to 155 weeks. In RESPONSE, 61.7% of patients met the endpoint at 12 months (M) vs 20% for placebo. In ASSURE, 61.8% (6M) and 72.4% (12M) met the composite endpoint; 75% (6M) and 93.8% (12M) of placebo crossover patients met the endpoint. In RESPONSE, ALP normalized in 25% of seladelpar and 0 placebo patients at 12M. With continued treatment, 33.3% (6M) and 17.2% (12M) had ALP normalization; 26.9% (6M) and 50% (12M) of crossover patients had ALP normalization. In ASSURE, 6-month change from baseline in pruritus NRS was similar to RESPONSE: −3.8 and −3.7 in continuous and crossover patients, respectively. At 12M and 24M, 73.2% and 69.7% of legacy patients met the endpoint in ASSURE; 42.1% and 42.4% achieved ALP normalization, and reduction in pruritus NRS was −3.8 and −3.1, respectively. There were no treatment-related serious adverse events. Conclusions: Seladelpar treatment led to improvements in biochemical markers and pruritus, and was well tolerated with long-term use.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.aohep.2024.101599
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4405119439
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4405119439Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.aohep.2024.101599Digital Object Identifier
- Title
-
OP-1 LONG-TERM EFFICACY AND SAFETY OF OPEN-LABEL SELADELPAR TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: INTERIM 2-YEAR RESULTS FROM THE ASSURE STUDYWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-12-01Full publication date if available
- Authors
-
Palak Trivedi, Cynthia Levy, Kris V. Kowdley, Stuart C. Gordon, Christopher L. Bowlus, Maria Carlota Londoño Hurtado, Gideon M. Hirschfield, Aliya F. Gulamhusien, Eric Lawitz, Alejandra Maria Villamil, Alma Ladron de Guevara Cetina, Marlyn J. Mayo, Ziad Younes, Oren Shibolet, Kidist Yimam, Daniel S. Pratt, Jeong Heo, Ulrike Morgera, Pietro Andreoné, Andreas E. Kremer, Christophe Corpechot, Aparna Goel, Adam Peyton, Hany Elbeshbeshy, Daria B. Crittenden, Carrie Heusner, Sarah Proehl, Shuqiong Zhou, Charles A. McWherterList of authors in order
- Landing page
-
https://doi.org/10.1016/j.aohep.2024.101599Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1016/j.aohep.2024.101599Direct OA link when available
- Concepts
-
Medicine, Interim, Interim analysis, Open label, Term (time), Internal medicine, Surgery, Gastroenterology, Clinical trial, History, Archaeology, Physics, Quantum mechanicsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4405119439 |
|---|---|
| doi | https://doi.org/10.1016/j.aohep.2024.101599 |
| ids.doi | https://doi.org/10.1016/j.aohep.2024.101599 |
| ids.openalex | https://openalex.org/W4405119439 |
| fwci | 0.0 |
| type | article |
| title | OP-1 LONG-TERM EFFICACY AND SAFETY OF OPEN-LABEL SELADELPAR TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: INTERIM 2-YEAR RESULTS FROM THE ASSURE STUDY |
| biblio.issue | |
| biblio.volume | 29 |
| biblio.last_page | 101599 |
| biblio.first_page | 101599 |
| topics[0].id | https://openalex.org/T10518 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9994999766349792 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Gallbladder and Bile Duct Disorders |
| topics[1].id | https://openalex.org/T12460 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9952999949455261 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2746 |
| topics[1].subfield.display_name | Surgery |
| topics[1].display_name | Pediatric Hepatobiliary Diseases and Treatments |
| topics[2].id | https://openalex.org/T11834 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9932000041007996 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2721 |
| topics[2].subfield.display_name | Hepatology |
| topics[2].display_name | Liver Diseases and Immunity |
| is_xpac | False |
| apc_list.value | 1500 |
| apc_list.currency | USD |
| apc_list.value_usd | 1500 |
| apc_paid.value | 1500 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 1500 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9621342420578003 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2776957806 |
| concepts[1].level | 2 |
| concepts[1].score | 0.8926355838775635 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q4895105 |
| concepts[1].display_name | Interim |
| concepts[2].id | https://openalex.org/C61943457 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6219587326049805 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q6046661 |
| concepts[2].display_name | Interim analysis |
| concepts[3].id | https://openalex.org/C3019800554 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5441170930862427 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q3813242 |
| concepts[3].display_name | Open label |
| concepts[4].id | https://openalex.org/C61797465 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5205546617507935 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1188986 |
| concepts[4].display_name | Term (time) |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.3848482668399811 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C141071460 |
| concepts[6].level | 1 |
| concepts[6].score | 0.34763312339782715 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[6].display_name | Surgery |
| concepts[7].id | https://openalex.org/C90924648 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3407818675041199 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[7].display_name | Gastroenterology |
| concepts[8].id | https://openalex.org/C535046627 |
| concepts[8].level | 2 |
| concepts[8].score | 0.27305448055267334 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q30612 |
| concepts[8].display_name | Clinical trial |
| concepts[9].id | https://openalex.org/C95457728 |
| concepts[9].level | 0 |
| concepts[9].score | 0.0 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q309 |
| concepts[9].display_name | History |
| concepts[10].id | https://openalex.org/C166957645 |
| concepts[10].level | 1 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q23498 |
| concepts[10].display_name | Archaeology |
| concepts[11].id | https://openalex.org/C121332964 |
| concepts[11].level | 0 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q413 |
| concepts[11].display_name | Physics |
| concepts[12].id | https://openalex.org/C62520636 |
| concepts[12].level | 1 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q944 |
| concepts[12].display_name | Quantum mechanics |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9621342420578003 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/interim |
| keywords[1].score | 0.8926355838775635 |
| keywords[1].display_name | Interim |
| keywords[2].id | https://openalex.org/keywords/interim-analysis |
| keywords[2].score | 0.6219587326049805 |
| keywords[2].display_name | Interim analysis |
| keywords[3].id | https://openalex.org/keywords/open-label |
| keywords[3].score | 0.5441170930862427 |
| keywords[3].display_name | Open label |
| keywords[4].id | https://openalex.org/keywords/term |
| keywords[4].score | 0.5205546617507935 |
| keywords[4].display_name | Term (time) |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.3848482668399811 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/surgery |
| keywords[6].score | 0.34763312339782715 |
| keywords[6].display_name | Surgery |
| keywords[7].id | https://openalex.org/keywords/gastroenterology |
| keywords[7].score | 0.3407818675041199 |
| keywords[7].display_name | Gastroenterology |
| keywords[8].id | https://openalex.org/keywords/clinical-trial |
| keywords[8].score | 0.27305448055267334 |
| keywords[8].display_name | Clinical trial |
| language | en |
| locations[0].id | doi:10.1016/j.aohep.2024.101599 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S32516778 |
| locations[0].source.issn | 1665-2681, 2659-5982 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1665-2681 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Annals of Hepatology |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Annals of Hepatology |
| locations[0].landing_page_url | https://doi.org/10.1016/j.aohep.2024.101599 |
| locations[1].id | pmh:oai:doaj.org/article:626163d451204fb3b08b87ac61157f74 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306401280 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].source.host_organization_lineage | |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | article |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Annals of Hepatology, Vol 29, Iss , Pp 101599- (2024) |
| locations[1].landing_page_url | https://doaj.org/article/626163d451204fb3b08b87ac61157f74 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5065028057 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-4009-8087 |
| authorships[0].author.display_name | Palak Trivedi |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Palak J. Trivedi |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5060508119 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-5498-6037 |
| authorships[1].author.display_name | Cynthia Levy |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Cynthia Levy |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5091028785 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-8553-3652 |
| authorships[2].author.display_name | Kris V. Kowdley |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Kris V. Kowdley |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5046835105 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-8666-3849 |
| authorships[3].author.display_name | Stuart C. Gordon |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Stuart C. Gordon |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5029813521 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-3906-6811 |
| authorships[4].author.display_name | Christopher L. Bowlus |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Christopher L. Bowlus |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5104247140 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Maria Carlota Londoño Hurtado |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Maria Carlota Londoño Hurtado |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5113993632 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Gideon M. Hirschfield |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Gideon M. Hirschfield |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5114391771 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Aliya F. Gulamhusien |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Aliya F. Gulamhusien |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5075322332 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-4234-224X |
| authorships[8].author.display_name | Eric Lawitz |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Eric J. Lawitz |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5074261970 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-7152-0976 |
| authorships[9].author.display_name | Alejandra Maria Villamil |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Alejandra Villamil |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5114986244 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Alma Ladron de Guevara Cetina |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Alma Ladron de Guevara Cetina |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5009192230 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-4874-7010 |
| authorships[11].author.display_name | Marlyn J. Mayo |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Marlyn J. Mayo |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5019006253 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-7382-3698 |
| authorships[12].author.display_name | Ziad Younes |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Ziad H. Younes |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5042378104 |
| authorships[13].author.orcid | https://orcid.org/0000-0003-0081-3872 |
| authorships[13].author.display_name | Oren Shibolet |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Oren Shibolet |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5081182142 |
| authorships[14].author.orcid | |
| authorships[14].author.display_name | Kidist Yimam |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Kidist K. Yimam |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5057057172 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-7426-969X |
| authorships[15].author.display_name | Daniel S. Pratt |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Daniel S. Pratt |
| authorships[15].is_corresponding | False |
| authorships[16].author.id | https://openalex.org/A5046190075 |
| authorships[16].author.orcid | https://orcid.org/0000-0003-0961-7851 |
| authorships[16].author.display_name | Jeong Heo |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Jeong Heo |
| authorships[16].is_corresponding | False |
| authorships[17].author.id | https://openalex.org/A5099059844 |
| authorships[17].author.orcid | |
| authorships[17].author.display_name | Ulrike Morgera |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Ulrike Morgera |
| authorships[17].is_corresponding | False |
| authorships[18].author.id | https://openalex.org/A5074836130 |
| authorships[18].author.orcid | https://orcid.org/0000-0002-4794-9809 |
| authorships[18].author.display_name | Pietro Andreoné |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Pietro Andreone |
| authorships[18].is_corresponding | False |
| authorships[19].author.id | https://openalex.org/A5081840796 |
| authorships[19].author.orcid | https://orcid.org/0000-0002-9263-948X |
| authorships[19].author.display_name | Andreas E. Kremer |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Andreas E. Kremer |
| authorships[19].is_corresponding | False |
| authorships[20].author.id | https://openalex.org/A5090413862 |
| authorships[20].author.orcid | https://orcid.org/0000-0002-7920-9784 |
| authorships[20].author.display_name | Christophe Corpechot |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Christophe Corpechot |
| authorships[20].is_corresponding | False |
| authorships[21].author.id | https://openalex.org/A5026980871 |
| authorships[21].author.orcid | https://orcid.org/0000-0001-9588-9364 |
| authorships[21].author.display_name | Aparna Goel |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Aparna Goel |
| authorships[21].is_corresponding | False |
| authorships[22].author.id | https://openalex.org/A5039486263 |
| authorships[22].author.orcid | |
| authorships[22].author.display_name | Adam Peyton |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Adam Peyton |
| authorships[22].is_corresponding | False |
| authorships[23].author.id | https://openalex.org/A5113023557 |
| authorships[23].author.orcid | |
| authorships[23].author.display_name | Hany Elbeshbeshy |
| authorships[23].author_position | middle |
| authorships[23].raw_author_name | Hany Elbeshbeshy |
| authorships[23].is_corresponding | False |
| authorships[24].author.id | https://openalex.org/A5025806056 |
| authorships[24].author.orcid | |
| authorships[24].author.display_name | Daria B. Crittenden |
| authorships[24].author_position | middle |
| authorships[24].raw_author_name | Daria B. Crittenden |
| authorships[24].is_corresponding | False |
| authorships[25].author.id | https://openalex.org/A5062050120 |
| authorships[25].author.orcid | |
| authorships[25].author.display_name | Carrie Heusner |
| authorships[25].author_position | middle |
| authorships[25].raw_author_name | Carrie Heusner |
| authorships[25].is_corresponding | False |
| authorships[26].author.id | https://openalex.org/A5010348335 |
| authorships[26].author.orcid | https://orcid.org/0009-0008-8255-3560 |
| authorships[26].author.display_name | Sarah Proehl |
| authorships[26].author_position | middle |
| authorships[26].raw_author_name | Sarah Proehl |
| authorships[26].is_corresponding | False |
| authorships[27].author.id | https://openalex.org/A5104325561 |
| authorships[27].author.orcid | |
| authorships[27].author.display_name | Shuqiong Zhou |
| authorships[27].author_position | middle |
| authorships[27].raw_author_name | Shuqiong Zhou |
| authorships[27].is_corresponding | False |
| authorships[28].author.id | https://openalex.org/A5044763036 |
| authorships[28].author.orcid | https://orcid.org/0000-0002-7613-3008 |
| authorships[28].author.display_name | Charles A. McWherter |
| authorships[28].author_position | last |
| authorships[28].raw_author_name | Charles A. McWherter |
| authorships[28].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1016/j.aohep.2024.101599 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | OP-1 LONG-TERM EFFICACY AND SAFETY OF OPEN-LABEL SELADELPAR TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: INTERIM 2-YEAR RESULTS FROM THE ASSURE STUDY |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10518 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9994999766349792 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Gallbladder and Bile Duct Disorders |
| related_works | https://openalex.org/W2381648486, https://openalex.org/W2023402573, https://openalex.org/W64094104, https://openalex.org/W2442977450, https://openalex.org/W3140988586, https://openalex.org/W4241346962, https://openalex.org/W4249829394, https://openalex.org/W2746117175, https://openalex.org/W2363503150, https://openalex.org/W2891422892 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1016/j.aohep.2024.101599 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S32516778 |
| best_oa_location.source.issn | 1665-2681, 2659-5982 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1665-2681 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Annals of Hepatology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Annals of Hepatology |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.aohep.2024.101599 |
| primary_location.id | doi:10.1016/j.aohep.2024.101599 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S32516778 |
| primary_location.source.issn | 1665-2681, 2659-5982 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1665-2681 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Annals of Hepatology |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Annals of Hepatology |
| primary_location.landing_page_url | https://doi.org/10.1016/j.aohep.2024.101599 |
| publication_date | 2024-12-01 |
| publication_year | 2024 |
| referenced_works_count | 0 |
| abstract_inverted_index./ | 63 |
| abstract_inverted_index.0 | 214 |
| abstract_inverted_index.3 | 33, 43 |
| abstract_inverted_index.10 | 158 |
| abstract_inverted_index.12 | 175 |
| abstract_inverted_index.As | 147 |
| abstract_inverted_index.At | 263 |
| abstract_inverted_index.In | 166, 182, 205, 241 |
| abstract_inverted_index.We | 54 |
| abstract_inverted_index.an | 28 |
| abstract_inverted_index.as | 125, 140 |
| abstract_inverted_index.at | 174, 217 |
| abstract_inverted_index.in | 19, 37, 76, 209, 247, 257, 276, 286, 307 |
| abstract_inverted_index.is | 27 |
| abstract_inverted_index.mg | 159 |
| abstract_inverted_index.no | 296 |
| abstract_inverted_index.of | 1, 15, 35, 91, 148, 169, 198, 211, 235, 270 |
| abstract_inverted_index.or | 46, 128 |
| abstract_inverted_index.to | 71, 121, 142, 163, 252, 305 |
| abstract_inverted_index.up | 162 |
| abstract_inverted_index.vs | 178 |
| abstract_inverted_index.× | 88 |
| abstract_inverted_index.(M) | 177 |
| abstract_inverted_index.12M | 264 |
| abstract_inverted_index.155 | 164 |
| abstract_inverted_index.158 | 150 |
| abstract_inverted_index.179 | 153 |
| abstract_inverted_index.20% | 179 |
| abstract_inverted_index.25% | 210 |
| abstract_inverted_index.50% | 233 |
| abstract_inverted_index.75% | 193 |
| abstract_inverted_index.ALP | 94, 102, 207, 228, 239, 282 |
| abstract_inverted_index.For | 113 |
| abstract_inverted_index.Key | 78 |
| abstract_inverted_index.NRS | 249, 288 |
| abstract_inverted_index.and | 9, 17, 52, 59, 65, 97, 101, 123, 145, 152, 186, 195, 213, 224, 232, 255, 259, 265, 268, 279, 284, 291, 310, 312 |
| abstract_inverted_index.for | 161, 180 |
| abstract_inverted_index.had | 227, 238 |
| abstract_inverted_index.led | 304 |
| abstract_inverted_index.met | 171, 189, 202, 273 |
| abstract_inverted_index.the | 172, 190, 203, 274 |
| abstract_inverted_index.was | 105, 119, 250, 289, 313 |
| abstract_inverted_index.(6M) | 185, 194, 223, 231 |
| abstract_inverted_index.12M. | 218 |
| abstract_inverted_index.24M, | 266 |
| abstract_inverted_index.Full | 4 |
| abstract_inverted_index.With | 219 |
| abstract_inverted_index.Yes, | 3 |
| abstract_inverted_index.acid | 73 |
| abstract_inverted_index.from | 41, 116, 130, 245 |
| abstract_inverted_index.over | 40 |
| abstract_inverted_index.sent | 6 |
| abstract_inverted_index.use. | 318 |
| abstract_inverted_index.well | 314 |
| abstract_inverted_index.were | 80, 134, 295 |
| abstract_inverted_index.with | 21, 68, 137, 316 |
| abstract_inverted_index.(12M) | 188, 197, 226, 234 |
| abstract_inverted_index.(NRS; | 111 |
| abstract_inverted_index.17.2% | 225 |
| abstract_inverted_index.26.9% | 230 |
| abstract_inverted_index.33.3% | 222 |
| abstract_inverted_index.42.1% | 278 |
| abstract_inverted_index.42.4% | 280 |
| abstract_inverted_index.61.7% | 168 |
| abstract_inverted_index.61.8% | 184 |
| abstract_inverted_index.69.7% | 269 |
| abstract_inverted_index.72.4% | 187 |
| abstract_inverted_index.73.2% | 267 |
| abstract_inverted_index.93.8% | 196 |
| abstract_inverted_index.<1.67 | 87 |
| abstract_inverted_index.Phase | 32, 42 |
| abstract_inverted_index.There | 294 |
| abstract_inverted_index.[ALP] | 86 |
| abstract_inverted_index.could | 74 |
| abstract_inverted_index.daily | 160 |
| abstract_inverted_index.entry | 120, 141 |
| abstract_inverted_index.limit | 90 |
| abstract_inverted_index.scale | 110 |
| abstract_inverted_index.total | 98 |
| abstract_inverted_index.trial | 34 |
| abstract_inverted_index.upper | 89 |
| abstract_inverted_index.using | 107 |
| abstract_inverted_index.2-year | 57 |
| abstract_inverted_index.ASSURE | 25 |
| abstract_inverted_index.[ULN], | 93 |
| abstract_inverted_index.change | 244 |
| abstract_inverted_index.enroll | 75 |
| abstract_inverted_index.legacy | 47, 132, 154, 271 |
| abstract_inverted_index.months | 176 |
| abstract_inverted_index.normal | 92 |
| abstract_inverted_index.rating | 109 |
| abstract_inverted_index.report | 55 |
| abstract_inverted_index.safety | 60 |
| abstract_inverted_index.weeks. | 165 |
| abstract_inverted_index.−3.7 | 256 |
| abstract_inverted_index.−3.8 | 254, 290 |
| abstract_inverted_index.6-month | 243 |
| abstract_inverted_index.ASSURE, | 183, 242 |
| abstract_inverted_index.ASSURE. | 77, 143 |
| abstract_inverted_index.ASSURE; | 277 |
| abstract_inverted_index.Results | 144 |
| abstract_inverted_index.adverse | 299 |
| abstract_inverted_index.biliary | 23 |
| abstract_inverted_index.defined | 139 |
| abstract_inverted_index.events. | 300 |
| abstract_inverted_index.interim | 56 |
| abstract_inverted_index.markers | 14, 309 |
| abstract_inverted_index.placebo | 199, 215 |
| abstract_inverted_index.primary | 22 |
| abstract_inverted_index.reduces | 12 |
| abstract_inverted_index.rolling | 39 |
| abstract_inverted_index.serious | 298 |
| abstract_inverted_index.similar | 251 |
| abstract_inverted_index.studies | 48 |
| abstract_inverted_index.−3.1, | 292 |
| abstract_inverted_index.≤ULN) | 100 |
| abstract_inverted_index.≥15%, | 96 |
| abstract_inverted_index.01/2024, | 149 |
| abstract_inverted_index.0–10). | 112 |
| abstract_inverted_index.Conflict | 0 |
| abstract_inverted_index.Methods: | 66 |
| abstract_inverted_index.Patients | 62, 67 |
| abstract_inverted_index.Pruritus | 104 |
| abstract_inverted_index.RESPONSE | 44, 122, 151 |
| abstract_inverted_index.achieved | 281 |
| abstract_inverted_index.analyzed | 124, 135 |
| abstract_inverted_index.baseline | 118, 138, 246 |
| abstract_inverted_index.decrease | 95 |
| abstract_inverted_index.efficacy | 58 |
| abstract_inverted_index.endpoint | 173, 275 |
| abstract_inverted_index.measured | 106 |
| abstract_inverted_index.ongoing, | 29 |
| abstract_inverted_index.patients | 20, 38, 114, 133, 155, 170, 201, 216, 237, 272 |
| abstract_inverted_index.placebo. | 181 |
| abstract_inverted_index.placebo; | 131 |
| abstract_inverted_index.pruritus | 18, 248, 287 |
| abstract_inverted_index.received | 156 |
| abstract_inverted_index.response | 83 |
| abstract_inverted_index.results. | 61 |
| abstract_inverted_index.(alkaline | 84 |
| abstract_inverted_index.Materials | 64 |
| abstract_inverted_index.RESPONSE, | 117, 167, 206 |
| abstract_inverted_index.RESPONSE: | 253 |
| abstract_inverted_index.bilirubin | 99 |
| abstract_inverted_index.composite | 81, 191 |
| abstract_inverted_index.continued | 220 |
| abstract_inverted_index.crossover | 129, 200, 236, 260 |
| abstract_inverted_index.endpoint. | 204 |
| abstract_inverted_index.endpoint; | 192 |
| abstract_inverted_index.endpoints | 79 |
| abstract_inverted_index.enrolling | 115 |
| abstract_inverted_index.interest: | 2 |
| abstract_inverted_index.long-term | 31, 317 |
| abstract_inverted_index.numerical | 108 |
| abstract_inverted_index.patients, | 261 |
| abstract_inverted_index.pruritus, | 311 |
| abstract_inverted_index.reduction | 285 |
| abstract_inverted_index.tolerated | 315 |
| abstract_inverted_index.treatment | 303 |
| abstract_inverted_index.Seladelpar | 11, 302 |
| abstract_inverted_index.continuous | 126, 258 |
| abstract_inverted_index.normalized | 208 |
| abstract_inverted_index.seladelpar | 36, 127, 157, 212 |
| abstract_inverted_index.separately | 136 |
| abstract_inverted_index.treatment, | 221 |
| abstract_inverted_index.Discussion: | 146 |
| abstract_inverted_index.Objectives: | 10 |
| abstract_inverted_index.biochemical | 13, 82, 308 |
| abstract_inverted_index.cholestasis | 16 |
| abstract_inverted_index.disclosures | 5 |
| abstract_inverted_index.open-label, | 30 |
| abstract_inverted_index.phosphatase | 85 |
| abstract_inverted_index.separately. | 7 |
| abstract_inverted_index.Conclusions: | 301 |
| abstract_inverted_index.Introduction | 8 |
| abstract_inverted_index.NCT02955602, | 50 |
| abstract_inverted_index.NCT03301506, | 51 |
| abstract_inverted_index.cholangitis. | 24 |
| abstract_inverted_index.improvements | 306 |
| abstract_inverted_index.insufficient | 69 |
| abstract_inverted_index.(NCT03301506) | 26 |
| abstract_inverted_index.(NCT03602560, | 49 |
| abstract_inverted_index.(NCT04620733) | 45 |
| abstract_inverted_index.NCT04950764). | 53 |
| abstract_inverted_index.respectively. | 262, 293 |
| abstract_inverted_index.normalization, | 283 |
| abstract_inverted_index.normalization. | 103, 240 |
| abstract_inverted_index.normalization; | 229 |
| abstract_inverted_index.ursodeoxycholic | 72 |
| abstract_inverted_index.treatment-related | 297 |
| abstract_inverted_index.response/intolerance | 70 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 29 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.41999998688697815 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.45553886 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |